Literature DB >> 34088356

Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk.

Iván Ferraz-Amaro1, Alfonso Corrales2,3, Juan Carlos Quevedo-Abeledo4, Nuria Vegas-Revenga2,3, Ricardo Blanco2,3, Virginia Portilla2,3, Belén Atienza-Mateo2,3, Miguel Á González-Gay2,3,5.   

Abstract

BACKGROUND: Previous studies have shown that risk chart algorithms, such as the Systematic Coronary Risk Assessment (SCORE), often underestimate the actual cardiovascular (CV) risk of patients with rheumatoid arthritis (RA). In contrast, carotid ultrasound was found to be useful to identify RA patients at high CV. In the present study, we aimed to determine if specific disease features influence the CV risk reclassification of RA patients assessed by SCORE risk charts and carotid ultrasound.
METHODS: 1279 RA patients without previous CV events, diabetes, or chronic kidney disease were studied. Disease characteristics including disease activity scores, CV comorbidity, SCORE calculation, and the presence of carotid plaque by carotid ultrasound were assessed. A multivariable regression analysis was performed to evaluate if the reclassification into very high CV risk category was independently associated with specific features of the disease including disease activity. Additionally, a prediction model for reclassification was constructed in RA patients.
RESULTS: After carotid ultrasound assessments, 54% of the patients had carotid plaque and consequently fulfilled definition for very high CV risk. Disease activity was statistically significantly associated with reclassification after fully multivariable analysis. A predictive model containing the presence of dyslipidemia and hypertension, an age exceeding 54 years, and a DAS28-ESR score equal or higher than 2.6 yielded the highest discrimination for reclassification.
CONCLUSION: Reclassification into very high CV risk after carotid ultrasound assessment occurs in more than the half of patients with RA. This reclassification can be independently explained by the activity of the disease.

Entities:  

Keywords:  Cardiovascular disease; Carotid plaque; Rheumatoid arthritis

Year:  2021        PMID: 34088356     DOI: 10.1186/s13075-021-02542-7

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  2 in total

1.  Reclassification into very-high cardiovascular risk after carotid ultrasound in patients with axial spondyloarthritis.

Authors:  Javier Rueda-Gotor; Juan Carlos Quevedo-Abeledo; Alfonso Corrales; Fernanda Genre; Vanesa Hernández-Hernández; Esmeralda Delgado-Frías; Miguel Ángel González-Gay; Ivan Ferraz-Amaro
Journal:  Clin Exp Rheumatol       Date:  2020-02-14       Impact factor: 4.473

2.  Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis.

Authors:  Amy H Kao; Shanthi Krishnaswami; Amylynn Cunningham; Daniel Edmundowicz; Penelope A Morel; Lewis H Kuller; Mary Chester M Wasko
Journal:  J Rheumatol       Date:  2008-01       Impact factor: 4.666

  2 in total
  2 in total

1.  Subclinical Atherosclerosis Measure by Carotid Ultrasound and Inflammatory Activity in Patients with Rheumatoid Arthritis and Spondylarthritis.

Authors:  Marta Rojas-Giménez; Clementina López-Medina; María Lourdes Ladehesa-Pineda; María Ángeles Puche-Larrubia; Ignacio Gómez-García; Jerusalem Calvo-Gutiérrez; Pedro Seguí-Azpilcueta; María Del Carmen Ábalos-Aguilera; Desirée Ruíz-Vilchez; Alejandro Escudero-Contreras; Eduardo Collantes-Estévez
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

2.  Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis.

Authors:  Marta Rojas-Giménez; Clementina López-Medina; Jerusalem Calvo-Gutiérrez; María Ángeles Puche-Larrubia; Ignacio Gómez-García; Pedro Seguí-Azpilcueta; María Del Carmen Ábalos-Aguilera; Desirée Ruíz; Eduardo Collantes-Estévez; Alejandro Escudero-Contreras
Journal:  Diagnostics (Basel)       Date:  2021-12-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.